Drape Eric
Known title: Executive VP Global OperationsCIK: 0001790905
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 55,226 | — | 3/5/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 19,515 | — | 2/28/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 9,815 | $129K | 2/28/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 173,261 | $2.3M | 2/16/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 4,699 | $44K | 3/7/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 1,566 | $16K | 3/6/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 11,940 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 19,514 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 9,797 | $97K | 2/28/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 47,598 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 23,888 | $236K | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 11,334 | $83K | 3/7/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 32,518 | — | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 11,940 | — | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,301 | $47K | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 17,157 | $128K | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 9,797 | $80K | 2/28/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 19,514 | — | 2/28/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 6,568 | — | 2/9/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 3,583 | $32K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.